Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics
02 December 2011
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in coagulation diagnostics with a focus on platelet function testing, the fastest growing field in the coagulation market. With the acquisition, Roche will be able to provide a comprehensive coagulation portfolio, ranging from self-monitoring applications to the high efficiency demands of hospital and commercial laboratories. The deal will help Roche gain further market share in the coagulation segment and thus further strengthen its leading position in the clinical diagnostic market.
“Improving the assessment of a patients’ platelet function status is currently a significant unmet need for hematologists, cardiologists and anesthetists in order to support clinical decisions in cardiology, surgery and intensive care,” said Colin Brown, Head of Roche Professional Diagnostics. “With this acquisition we gain an innovative and unique platelet function testing solution which has the potential to set new standards of patient care in this area and perfectly complements our new coagulation portfolio.” Coagulation diagnostics has become an important area in clinical diagnostics and Roche has already begun with significant investments, heralding a new era in this field.
Under the terms of the acquisition agreement, Roche will pay Verum Diagnostica shareholders a total cash consideration of eleven million euros, and potentially a further two million euros contingent upon reaching certain performance-related milestones. The transaction is subject to customary closing conditions and is expected to close in January 2012.
Verum Diagnostica’s Multiplate® system allows the rapid and sensitive analysis of platelet function which aids clinicians to determine which anti-platelet therapy a patient will best respond to after heart attack and stent placement and to prevent bleeding complications during and after surgical procedures. Both applications will help to improve patient’s treatment and reduce complications along with the associated costs. The system’s superior performance and cost-effectiveness further support the efficiency needs of hospital laboratories and critical care settings.
“With its leadership position in in-vitro diagnostics (IVD) and its global reach, Roche is the ideal company to broadly commercialize, accelerate clinical adoption and further develop the Multiplate technology. We anticipate the ongoing development of applications for both near patient settings and high volume testing in the central laboratory,” stated Dr. Andreas Calatzis, CEO and Co-Founder of Verum Diagnostica, and Co-Inventor of the Multiplate technology. “We are very excited about entering the next stage of our life cycle and to make our products available to patients and physicians, now on a global scale. “
The laboratory coagulation market is estimated at 1.33 billion USD in 2010 with a projected annual growth rate of 5.1% over the next five years. Platelet function testing has the potential to expand the available market significantly and represents an unmet medical need. Roche will significantly invest into clinical studies that demonstrate the novel clinical utility of the Multiplate system for clinicians, patients and the entire healthcare system. In addition, Roche is also developing new testing instruments and reagents for the coagulation market as part of its on-going efforts to meet both the clinical and testing efficiency needs of professional IVD customers.
About Verum Diagnostica
Verum Diagnostica GmbH is a 100 percent subsidiary of Dynabyte Informationssysteme GmbH, developing, producing and marketing the Multiplate analyzer, test cells and reagents for the determination of platelet function in whole blood for use in hospital laboratories and near-patient settings, such as interventional cardiology, surgery and intensive care. Operating globally in more than 45 countries, the company is based in the biotech cluster and academic center of Munich, Germany, and closely cooperates with an extensive network of clinical partners. Verum Diagnostica will become part of Roche’s Professional Diagnostics business area.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com
All trademarks used or mentioned in this release are protected by law.